{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:55:46Z","timestamp":1780422946753,"version":"3.54.1"},"reference-count":28,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.3892\/etm.2016.3738","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T11:03:51Z","timestamp":1474455831000},"page":"3041-3046","source":"Crossref","is-referenced-by-count":15,"title":["Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma"],"prefix":"10.3892","volume":"12","author":[{"given":"Hong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,9,21]]},"reference":[{"key":"key20180108132908_b1-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2141.2004.05207.x","article-title":"Consultant Haematologists, South Thames Haematology Specialist Committee: A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK","volume":"127","author":"Phekoo","year":"2004","journal-title":"Br J Haematol"},{"key":"key20180108132908_b2-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00277-013-1828-8","article-title":"Bortezomib and dexamethasone as salvage therapy in patients with relapsed\/refractory multiple myeloma: Analysis of long-term clinical outcomes","volume":"93","author":"Pantani","year":"2014","journal-title":"Ann Hematol"},{"key":"key20180108132908_b3-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20180108132908_b4-etm-0-0-3738","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"key20180108132908_b5-etm-0-0-3738","first-page":"537","article-title":"Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy","volume":"57","author":"Ri","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"key20180108132908_b6-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.084376","article-title":"Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"key":"key20180108132908_b7-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"key":"key20180108132908_b8-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"key":"key20180108132908_b9-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-0925-1","article-title":"Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma","volume":"89","author":"Palumbo","year":"2010","journal-title":"Ann Hematol"},{"key":"key20180108132908_b10-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"key20180108132908_b11-etm-0-0-3738","unstructured":"National Cancer InstituteCommon terminology criteria for adverse events, version 3.0https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdfAccessedApril112011"},{"key":"key20180108132908_b12-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108132908_b13-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40265-013-0006-6","article-title":"Subcutaneous bortezomib: In multiple myeloma","volume":"73","author":"Hoy","year":"2013","journal-title":"Drugs"},{"key":"key20180108132908_b14-etm-0-0-3738","first-page":"167","article-title":"Subcutaneous bortezomib as a new promising way to successful maintenance therapy in multiple myeloma","volume":"65","author":"Grosicki","year":"2012","journal-title":"Wiad Lek"},{"key":"key20180108132908_b15-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The MMVAR\/IFM 2005-04 Randomized phase III trial from the chronic leukemia working party of the European group for blood and marrow transplantation","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180108132908_b16-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am J Hematol"},{"key":"key20180108132908_b17-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"key":"key20180108132908_b18-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000355197","article-title":"Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma","volume":"85","author":"Lamm","year":"2013","journal-title":"Oncology"},{"key":"key20180108132908_b19-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"key20180108132908_b20-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","article-title":"Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy","volume":"16","author":"Wright","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"key20180108132908_b21-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood.V118.21.476.476","article-title":"Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma and no increased risk of second primary malignancies: Final results of the phase 3 VISTA trial","volume":"118","author":"San Miguel","year":"2011","journal-title":"Blood"},{"key":"key20180108132908_b22-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000322866","article-title":"Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland","volume":"79","author":"Hrusovsky","year":"2010","journal-title":"Oncology"},{"key":"key20180108132908_b23-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2141.2011.08703.x","article-title":"A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients","volume":"154","author":"Sher","year":"2011","journal-title":"Br J Haematol"},{"key":"key20180108132908_b24-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"key":"key20180108132908_b25-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neuro.2007.11.003","article-title":"Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover and induction in the neuronal cells in vitro","volume":"29","author":"Csizmadia","year":"2008","journal-title":"Neurotoxicology"},{"key":"key20180108132908_b26-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.23358","article-title":"Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma","volume":"88","author":"Mangiacavalli","year":"2013","journal-title":"Am J Hematol"},{"key":"key20180108132908_b27-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"key20180108132908_b28-etm-0-0-3738","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.12070","article-title":"Weekly intravenous bortezomib is effective and well tolerated in relapsed\/refractory myeloma","volume":"90","author":"Moore","year":"2013","journal-title":"Eur J Haematol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2016.3738\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T05:09:09Z","timestamp":1601096949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2016.3738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,21]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,9,21]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.3892\/etm.2016.3738"],"URL":"https:\/\/doi.org\/10.3892\/etm.2016.3738","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,21]]}}}